Adrenal Venous Sampling Via an Antecubital Approach in Primary Aldosteronism: A Multicenter Study.
J Clin Endocrinol Metab
; 109(1): e274-e279, 2023 Dec 21.
Article
in En
| MEDLINE
| ID: mdl-37466201
ABSTRACT
CONTEXT Adrenal venous sampling (AVS) is considered the gold standard for differentiating unilateral and bilateral forms of primary aldosteronism. Currently, almost all AVS procedures are performed via femoral vein access. OBJECTIVE:
The aim of this study was to evaluate the success rate and safety of AVS via an antecubital approach.METHODS:
In a retrospective multicenter study involving 7 Chinese medical centers, patients with primary aldosteronism who underwent AVS via an antecubital approach between January 2012 and December 2018 were analyzed. Successful sampling was determined by a selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava) greater than 2.RESULTS:
A total of 1226 participants (mean age, 47.1 years; 57.9% male) were included. The puncture site was right and left antecubital vein in 1211 (98.8%), and 15 (1.2%) patients. The access of 6 patients (0.5%) was changed to right femoral vein due to the failure of antecubital vein cannulation or anatomic variation of adrenal vein. The success rate of bilateral, right, and left sampling was 91.5%, 94.9%, and 95.1%, respectively. The success rate of bilateral, right, and left sampling increased from 82.9%, 87.1%, and 88.6% during the initial 70 cases (total of initial 10 cases at each center) to 92.0% (P = .012), 95.3% (P = .008), and 95.5% (P = .018) with subsequent cases. Adrenal vein rupture occurred in 5 patients (0.41%), with no sequelae.CONCLUSION:
This multicenter study demonstrates that AVS via an antecubital approach is safe and feasible, with a high rate of successful sampling, which may be an alternative to the femoral vein access method.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hyperaldosteronism
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Clin Endocrinol Metab
Year:
2023
Document type:
Article
Affiliation country:
China